MICS IOL modification does not affect PCO

Article

Modifying a MICS IOL from a 3-piece to a 1-piece haptic design does not cause any significant changes in PCO amount.

Modifying a MICS IOL from a 3-piece to a 1-piece haptic design does not cause any significant changes in PCO amount, according to recently produced data.

A research team led by Dr Birgit Weingessel, Department of Ophthalmology, Hietzing Hospital, Vienna, Austria, studied 80 eyes of 40 patients with age-related cataract.

Each participant received a 1-piece MICS IOL in one eye and a 3-piece MICS IOL in the other. After one year of follow-up patients were assessed using a slit-lamp. High-resolution images were taken to determine PCO amount and visual acuity was measured accordingly.

Mean regeneratory PCO score and the neodymium-yttrium-aluminium-garnet laser capsulotomy rate were significantly low for both IOLs. But capsular folds occurred more often in the eyes that were administered the 3-piece IOL.

The abstract can be found in the January edition of the British Journal of Ophthalmology.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.